Status:
COMPLETED
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Lead Sponsor:
Telik
Conditions:
Mantle Cell Lymphoma
B Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study wil...
Eligibility Criteria
Inclusion
- relapsed or refractory disease
- histologically or cytologically confirmed disease
- characteristic immunophenotypic profiles
- measurable disease (for lymphoma patients)
- ECOG performance status of 0-2
- adequate liver and kidney function
- adequate bone marrow reserves
- ineligible or unwilling to undergo autologous stem cell transplantation
Exclusion
- failure to recover from any major surgery within 4 weeks of study entry
- pregnant or lactating women
- women of child-bearing potential not using reliable and appropriate contraception
- routine prophylactic use of G-CSF required within 2 weeks of study entry
- Grade 3 or higher peripheral neuropathy
- history of hepatitis B virus or HIV
- central nervous system or meningeal involvement by lymphoma or multiple myeloma
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01148108
Start Date
June 1 2010
End Date
September 1 2012
Last Update
March 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901